COMPANY

INTELLECTUAL PROPERTY

  • ANL - 101

    AD/PD/MCI therapeutic agent

    • 등록

      KOREA (December, 2017)
      USA (July, 2020)
      CHINA (June, 2021)

    • 출원

      CHINA, PCT(Jun, 2016 )

  • ANL - 104

    Agent for Degenerative Obesity & Diabetes

    • 등록

      In Korea(January, 2021)

    • 출원

      In Korea(September, 2017)

  • ANL-105

    Agent for Epilepsy

    • 등록

      In Korea (April, 2021)

    • 출원

      In Korea (December, 2017)

  • AAV Composition, etc

    Composition for AAV delivery and AAV delivery efficiency screening method

    • 등록

    • 출원

      KOREA (June, 2023)

  • aMCI biomarker patent application

    Biomarkers for diagnosis of cognitive decline

    • 등록

    • 출원

      KOREA (June, 2023)

  • AI-based AAV discovery platform

    Filed a patent applicaion for INSIGHTMINER, an AI-driven AAV Engineering platform

    • 등록

    • 출원

      KOREA (June, 2023)

  • ANL-301

    Patent for the treatment of Lafora's disease

    • 등록

    • 출원

      KOREA (July, 2023)